1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 140,00 | 142,00 | 07.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Belite Bio, Inc: Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results | 1 | GlobeNewswire (USA) | ||
| 22.07. | Belite Bio stock price target maintained at $200 by H.C. Wainwright | 2 | Investing.com | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 20.07. | Why Is Belite Bio Stock Gaining Monday? | 2 | Benzinga.com | ||
| 20.07. | Belite Bio presents additional Phase 3 trial data for tinlarebant | 4 | Investing.com | ||
| 20.07. | Belite Bio, Inc: Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 | 1 | GlobeNewswire (USA) | ||
| 09.07. | Belite Bio: Phase-3-Daten stützen Zulassungsantrag für Tinlarebant | 5 | Investing.com Deutsch | ||
| 16.06. | Belite Bio: H.C. Wainwright bestätigt Kursziel von 200 Dollar nach Abschluss des Zulassungsantrags | 1 | Investing.com Deutsch | ||
| 16.06. | Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion | 3 | Investing.com | ||
| 13.06. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.06. | Belite Bio, Inc: Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 | 598 | GlobeNewswire (Europe) | SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting... ► Artikel lesen | |
| 01.06. | Full Transcript: Belite Bio Q1 2026 Earnings Call | 2 | Benzinga.com | ||
| 26.05. | Mizuho lowers Belite Bio stock price target to $215 on valuation | 2 | Investing.com | ||
| 22.05. | Benchmark reiterates Belite Bio stock rating on drug development progress | 5 | Investing.com | ||
| 21.05. | H.C. Wainwright reiterates Belite Bio stock rating on NDA progress | 2 | Investing.com | ||
| 21.05. | Belite Bio targets completing stargardt NDA rolling submission in Q2 2026 while planning a 30-40 member U.S. launch team | 2 | Seeking Alpha | ||
| 20.05. | Belite Bio übertrifft EPS-Prognose für Q1 2026, Aktie gibt dennoch nach | 3 | Investing.com Deutsch | ||
| 20.05. | Belite Bio Non-GAAP EPS of -$0.34 beats by $0.30 | 3 | Seeking Alpha | ||
| 20.05. | Belite Bio übertrifft Erwartungen im ersten Quartal - Aktie legt zu | 3 | Investing.com Deutsch | ||
| 20.05. | Belite Bio, Inc: Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update | 473 | GlobeNewswire (Europe) | Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected... ► Artikel lesen | |
| 20.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 46,430 | +0,32 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,770 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings | INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform... ► Artikel lesen | |
| ABIVAX | 113,90 | +3,64 % | EQS-News: ABIVAX: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | EQS-News: ABIVAX
/ Key word(s): Regulatory Admission
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30.07.2026 / 22:05 CET/CEST
The issuer... ► Artikel lesen | |
| GERON | 1,375 | +7,72 % | GERON CORP - 8-K, Current Report | ||
| CELLECTAR BIOSCIENCES | 2,560 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| ARGENX | 750,00 | +0,16 % | JPMORGAN stuft Argenx auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Argenx nach Zahlen zum zweiten Quartal mit einem Kursziel von 950 Euro auf "Overweight" belassen. Analyst Richard Vosser erhöhte... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,216 | 0,00 % | Rendite-Turbo mit KI und Smart Farming! Aufwärts geht's mit BASF, MustGrow, SAP und Nestle | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Horror-Waldbrände in Spanien und Südfrankreich - keine Seltenheit mehr in den letzten Jahren. Der Klimawandel fordert seinen Tribut.... ► Artikel lesen | |
| CYTOKINETICS | 66,28 | -0,12 % | Cytokinetics, Incorporated: Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update | MYQORZO- (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,929 | +0,83 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| ZAI LAB LTD ADR | 20,600 | +1,98 % | Citi Raises Zai Lab Limited TP to USD45, Expects China Business to Stabilize in 2H26 | ||
| CYBIN | 9,840 | -1,99 % | No Brainer Club: +205% in 2 Monaten mit Helus Pharma | Mit Helus Pharma hat der No Brainer Club erneut gezeigt, wie konsequentes Risikomanagement und diszipliniertes Handeln bei Biotech-Investments langfristig den Unterschied machen können. Bereits im Herbst... ► Artikel lesen | |
| XBIOTECH | 1,960 | 0,00 % | XBiotech Inc.: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis | IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:... ► Artikel lesen | |
| KYNTRA BIO | 5,800 | +0,87 % | Kyntra Bio to Report Second Quarter 2026 Financial Results |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +2,00 (+1,44 %) liegt der Kurs bei 141,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.